Burke P J, Karp J E, Geller R B, Vaughan W P
Johns Hopkins Oncology Center, Baltimore, MD 21205.
Leukemia. 1989 Oct;3(10):692-4.
A cure rate can be obtained with intensive cytoreductive treatment given to a subset of patients with acute myelocytic leukemia in bone marrow remission. This report updates our experience with postremission timed sequential therapy using cytarabine and daunorubicin (Ac-D-Ac) and compares it with other brief, aggressive strategies including bone marrow transplantation. The median disease-free survival (DFS) of all patients treated in remission is 2.5 years with a greater than 40% probability of DFS at 8 years. These results are similar to those achieved with bone marrow-ablative and other intensive but nonablative treatment plans.
对于一部分处于骨髓缓解期的急性髓细胞白血病患者，采用强化细胞减灭治疗可获得治愈率。本报告更新了我们使用阿糖胞苷和柔红霉素进行缓解后定时序贯治疗（Ac-D-Ac）的经验，并将其与包括骨髓移植在内的其他短期积极策略进行了比较。所有缓解期接受治疗患者的无病生存期（DFS）中位数为2.5年，8年时DFS概率大于40%。这些结果与采用骨髓清除性及其他强化但非清除性治疗方案所取得的结果相似。
